Combining Belimumab with Rituximab as a Treatment Strategy for Severe Systemic Lupus Erythematosus and Lupus Nephritis (ACR Convergence 2026) - Oct 16, 2026 - Abstract #LB07; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; "All patients received mycophenolate mofetil and prednisolone, with prednisolone tapering to 7.5 mg by week 28 and 5 mg by week 52. The combination of belimumab/rituximab demonstrated superior efficacy in severe SLE and lupus nephritis in reducing treatment failure, while eliminating long-term dependence on antiproliferative therapy. Figure 1: Treatment failure The intention-to-treat population included 71 patients; 35 assigned to standard of care (SoC) and 36 assigned to belimumab-rituximab (BEL/RTX). A: Kaplan-Meier estimates of time to treatment failure."
Late-breaking abstract • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Systemic Lupus Erythematosus
|
|
Mieke van Schaik 1; Eline Arends 2; Jolijn van Leeuwen 3; Edwin Bredewold 2; Lars van Vliet 2; Koen de Koning 2; Darius Soonawala 4; Maarten Limper 5; Ellen van Ommen 6; Karina de Leeuw 7; Marjolein Wetzels 2; Roula Tsonaka 2; Tom Huizinga 2; Ton Rabelink 2; Jolien Suurmond 2; Cees van Kooten 2; and Onno Teng 2
|